Watch the recording of The Valor Study for Dermatomyositis
The purpose of the VALOR Study is to learn more about the effectiveness and safety of the investigational medication brepocitinib in adults living with dermatomyositis. Investigational medicine means that it has not been approved by country-specific regulatory health authorities to be used for dermatomyositis and its use is being allowed for research purposes only. Brepocitinib will be compared to a placebo (placebo looks like brepocitinib but contains no active medicine). Participants in the study will take 3 tablets by mouth every day.
Participants in the study must have both muscle and skin problems caused by dermatomyositis. Brepocitinib is designed to block the part of the immune system involved in causing the inflammation seen in dermatomyositis.
Eligible participants for the trial must:
- Be 18 to 74 years old
- Have a diagnosis of dermatomyositis previously confirmed by a healthcare provider
- There are additional eligibility requirements, which the study doctor will explain. To learn more about study participation, and to see if you or someone you know may qualify, visit the VALOR study website.
Joining us from Priovant:
Noriko Iikuni VP, Clinical Development
Noriko Iikuni, MD, Ph.D., FACP is VP, Clinical Development at Priovant Therapeutics. Noriko is a board-certified rheumatologist and internist who brings extensive experience in clinical development, medical affairs, and pharmacovigilance across therapeutic areas including rheumatology, immunology, dermatology, gastroenterology, cardiovascular, diabetes, and men’s/women’s health. Prior to joining Priovant, Noriko helped lead late-stage dermatomyositis clinical trials at Alexion and JAK inhibitor development at Pfizer and Eli Lilly. Noriko holds a BS in Biology from Lafayette College, an MD from Kanazawa Medical University (Japan), and a PhD in Rheumatology at Tokyo Women’s Medical University. Noriko also completed a postdoctoral fellowship at the University of California, Los Angeles.
Barbara Zupancic, Head of Patient Enrollment and Engagement
Barbara Zupancic is Head of Patient Enrollment and Engagement at Priovant Therapeutics. Barbara has over 18 years of experience in clinical research, specifically focused on patient engagement and site support strategies. Most recently, Barbara was Senior Director, Global Patient Recruitment Optimization at Worldwide Clinical Trials, a global CRO. Barbara holds a BS in Psychology from Hunter College, an MSc in Counseling Psychology from Georgia State University, and an MBA from Baruch College.
Taryn Smith, Patient Evaluation Manager
Taryn Smith, PA-C is the Patient Evaluation Manager at Priovant Therapeutics. Taryn is an experienced clinician with almost a decade of experience caring for patients in the fields of Immunology, Asthma/allergy, Urogynecology and Psychiatry. Before becoming a physician assistant, she worked for the Oklahoma Medical Research Foundation and served as a Fleming Scholar. Taryn holds a BS in Nutritional Science summa cum laude from Oklahoma State University and a Master’s of Health Science from the University of Oklahoma Health Sciences Center.